Last 48 quarters of trend data · Healthcare · Medical Supplies & Consumables
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 21.58 | 21.04 | 20.53 | 18.90 | 17.44 | 19.20 | 15.14 | 15.23 | 17.87 | 16.40 | 17.04 | 16.31 | 17.84 | 19.91 | 20.26 | 20.42 | 20.11 | 18.07 | 19.17 | 23.40 | 22.12 |
| — | +9.6% | +35.6% | +24.1% | -2.4% | +17.1% | -11.2% | -6.6% | +0.1% | -17.6% | -15.9% | -20.1% | -11.3% | +10.1% | +5.7% | -12.7% | -9.1% | -10.4% | -15.2% | -10.3% | -2.4% | |
| P/S Ratio | 6.59 | 6.83 | 6.44 | 5.66 | 4.95 | 5.15 | 4.64 | 4.78 | 5.69 | 5.81 | 5.67 | 5.67 | 6.20 | 6.26 | 6.59 | 6.88 | 6.73 | 5.98 | 5.84 | 6.68 | 7.10 |
| — | +32.7% | +38.7% | +18.5% | -13.0% | -11.5% | -18.2% | -15.8% | -8.2% | -7.1% | -13.9% | -17.6% | -7.9% | +4.6% | +12.9% | +3.0% | -5.2% | -11.4% | -5.3% | -7.4% | +10.8% | |
| P/B Ratio | 1.96 | 1.91 | 1.80 | 1.64 | 1.50 | 1.71 | 1.57 | 1.58 | 1.77 | 1.87 | 1.90 | 2.01 | 2.38 | 2.53 | 2.79 | 2.92 | 3.20 | 2.87 | 2.92 | 3.02 | 3.42 |
| — | +11.9% | +14.5% | +3.5% | -15.4% | -8.9% | -17.4% | -21.3% | -25.5% | -25.9% | -31.7% | -31.0% | -25.5% | -11.7% | -4.5% | -3.2% | -6.6% | -7.2% | +0.8% | -0.0% | +14.3% | |
| P/FCF | 30.28 | — | 43.96 | 16.57 | 13.28 | 13.11 | 16.37 | 10.83 | 17.78 | 14.57 | 22.29 | 12.24 | 14.58 | 15.85 | 18.46 | 12.54 | 16.19 | 14.71 | 17.00 | 17.12 | 19.37 |
| — | — | +168.6% | +52.9% | -25.3% | -10.0% | -26.6% | -11.5% | +22.0% | -8.1% | +20.7% | -2.3% | -10.0% | +7.8% | +8.6% | -26.8% | -16.4% | +2.5% | -2.0% | +19.5% | +44.0% | |
| EV / EBITDA | 11.70 | 12.34 | 19.12 | 8.51 | 7.33 | 8.76 | 6.52 | 6.61 | 8.58 | 8.88 | 8.92 | 8.97 | 10.72 | 13.62 | 13.69 | 10.64 | 10.68 | 8.74 | 9.06 | 10.42 | 11.04 |
| — | +40.8% | +193.0% | +28.8% | -14.5% | -1.3% | -26.9% | -26.3% | -20.0% | -34.8% | -34.8% | -15.7% | +0.4% | +55.8% | +51.1% | +2.1% | -3.3% | -12.1% | -4.8% | -8.5% | +4.6% | |
| EV / EBIT | 12.67 | 11.06 | 16.72 | 8.66 | 7.52 | 8.91 | 6.70 | 7.39 | 9.61 | 8.65 | 8.73 | 8.85 | 11.57 | 16.40 | 16.42 | 13.61 | 12.66 | 11.28 | 11.91 | 14.56 | 14.85 |
| — | +24.2% | +149.5% | +17.3% | -21.7% | +3.0% | -23.2% | -16.5% | -16.9% | -47.3% | -46.9% | -35.0% | -8.6% | +45.4% | +37.9% | -6.5% | -14.8% | -15.6% | -8.7% | -13.0% | -0.9% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.1% | 56.1% | 55.8% | 60.6% | 58.2% | 57.1% | 56.2% | 57.0% | 58.1% | 58.0% | 60.1% | 59.7% | 57.6% | 45.9% | 47.6% | 62.6% | 61.3% | 63.2% | 60.7% | 61.1% | 62.8% |
| — | -1.7% | -0.8% | +6.2% | +0.1% | -1.5% | -6.5% | -4.4% | +1.0% | +26.3% | +26.2% | -4.8% | -6.2% | -27.3% | -21.5% | +2.5% | -2.4% | -1.6% | -1.7% | +26.9% | +3.9% | |
| Operating Margin | 29.6% | 32.4% | 31.1% | 29.4% | 27.0% | 26.6% | 32.1% | 32.5% | 32.0% | 33.4% | 33.1% | 34.2% | 32.0% | 31.7% | 34.4% | 35.5% | 37.4% | 39.7% | 37.7% | 36.7% | 39.7% |
| — | +21.8% | -3.3% | -9.4% | -15.6% | -20.4% | -2.9% | -5.2% | +0.0% | +5.3% | -3.9% | -3.4% | -14.4% | -20.0% | -8.7% | -3.4% | -6.0% | -2.1% | -0.4% | +3.5% | +11.5% | |
| Net Margin | 29.3% | 32.3% | 31.5% | 29.9% | 28.4% | 26.8% | 30.6% | 31.3% | 31.7% | 35.6% | 33.2% | 34.9% | 34.8% | 31.5% | 32.6% | 33.7% | 33.6% | 33.0% | 30.6% | 28.7% | 32.0% |
| — | +20.6% | +2.8% | -4.7% | -10.5% | -24.7% | -7.8% | -10.2% | -8.8% | +13.2% | +1.7% | +3.6% | +3.6% | -4.8% | +6.8% | +17.4% | +4.9% | -1.2% | +12.4% | +4.0% | +12.6% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 9.5% | 2.3% | 2.2% | 2.2% | 2.2% | 2.2% | 2.6% | 2.6% | 2.4% | 2.9% | 2.7% | 3.1% | 3.4% | 3.2% | 3.5% | 3.6% | 4.1% | 4.0% | 3.8% | 3.3% | 3.8% |
| — | +1.8% | -14.7% | -16.2% | -10.0% | -22.3% | -5.3% | -16.1% | -29.4% | -10.5% | -21.7% | -14.8% | -16.9% | -19.2% | -7.5% | +11.0% | +7.6% | +2.6% | +17.3% | +12.2% | +12.2% | |
| ROA | 9.2% | 2.2% | 2.2% | 2.1% | 2.1% | 2.2% | 2.5% | 2.5% | 2.3% | 2.7% | 2.6% | 2.9% | 3.2% | 3.0% | 3.3% | 3.3% | 3.8% | 3.6% | 3.5% | 3.0% | 3.5% |
| — | +1.6% | -13.9% | -15.0% | -8.8% | -21.0% | -3.7% | -15.0% | -28.4% | -8.8% | -20.0% | -12.8% | -14.5% | -17.6% | -6.5% | +11.6% | +7.1% | +2.6% | +17.3% | +12.2% | +12.6% | |
| ROIC | 25.0% | 2.6% | 2.6% | 5.7% | 5.4% | 5.6% | 6.9% | 6.9% | 6.2% | 7.0% | 7.4% | 8.3% | 3.7% | 2.4% | 4.2% | 8.6% | 9.7% | 9.6% | 8.9% | 7.5% | 8.3% |
| — | -53.4% | -62.9% | -16.4% | -13.2% | -20.4% | -7.4% | -17.3% | +68.0% | +192.0% | +79.1% | -3.8% | -61.8% | -74.8% | -53.3% | +15.1% | +16.4% | +17.8% | +21.2% | +29.9% | +34.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | -28.4% | -26.6% | -24.1% | -21.4% | -15.3% | -1.8% | +3.0% | +4.4% | -2.4% | -14.3% | -19.7% | -23.0% | -24.6% | -24.4% | -20.6% | -19.2% | +4.9% | +3.3% | +11.5% | +13.4% | |
| Debt / EBITDA | 0.02 | 0.06 | 0.07 | 0.06 | 0.07 | 0.07 | 0.06 | 0.07 | 0.08 | 0.07 | 0.07 | 0.06 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 |
| — | -17.6% | +4.4% | -6.6% | -8.3% | -2.5% | -2.7% | +11.2% | +29.8% | +38.6% | +31.5% | +18.0% | +18.5% | +3.1% | -5.7% | -12.4% | -12.3% | +3.8% | -0.0% | +5.0% | +3.7% | |
| Current Ratio | 37.62 | 21.23 | 48.62 | 28.64 | 37.62 | 32.06 | 41.87 | 22.29 | 25.64 | 29.59 | 25.98 | 19.57 | 22.56 | 24.38 | 19.21 | 15.66 | 15.09 | 13.44 | 17.79 | 13.03 | 19.53 |
| — | -33.8% | +16.1% | +28.5% | +46.7% | +8.3% | +61.2% | +13.9% | +13.6% | +21.4% | +35.2% | +25.0% | +49.5% | +81.4% | +8.0% | +20.1% | -22.8% | -11.1% | +11.7% | -10.6% | +18.9% | |
| Quick Ratio | 34.57 | 19.00 | 44.27 | 26.15 | 34.57 | 29.36 | 38.22 | 20.29 | 23.29 | 26.94 | 23.68 | 17.89 | 20.53 | 22.06 | 17.24 | 14.02 | 13.61 | 12.11 | 16.13 | 11.83 | 17.77 |
| — | -35.3% | +15.8% | +28.9% | +48.4% | +9.0% | +61.4% | +13.5% | +13.5% | +22.1% | +37.3% | +27.6% | +50.9% | +82.1% | +6.9% | +18.6% | -23.4% | -12.7% | +10.9% | -10.9% | +20.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying UTMD stock.
Utah Medical Products, Inc.'s current P/E is 21.6x. The average P/E over the last 4 quarters is 19.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Utah Medical Products, Inc.'s current operating margin is 29.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Utah Medical Products, Inc.'s business trajectory between earnings reports.